MRK vs. NVO
Compare and contrast key facts about Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: MRK or NVO.
Key characteristics
| MRK | NVO | |
|---|---|---|
| YTD Return | 20.35% | 23.68% |
| 1Y Return | 13.15% | 52.43% |
| 3Y Return (Ann) | 24.18% | 51.53% |
| 5Y Return (Ann) | 15.27% | 41.19% |
| 10Y Return (Ann) | 12.92% | 21.13% |
| Sharpe Ratio | 0.79 | 1.78 |
| Daily Std Dev | 17.46% | 32.21% |
| Max Drawdown | -68.63% | -71.28% |
| Current Drawdown | -1.19% | -5.87% |
Fundamentals
| MRK | NVO | |
|---|---|---|
| Market Cap | $322.99B | $548.93B |
| EPS | $0.91 | $2.87 |
| PE Ratio | 140.12 | 42.87 |
| PEG Ratio | 0.10 | 2.40 |
| Revenue (TTM) | $61.40B | $244.24B |
| Gross Profit (TTM) | $42.08B | $148.51B |
| EBITDA (TTM) | $10.36B | $117.85B |
Correlation
The correlation between MRK and NVO is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
MRK vs. NVO - Performance Comparison
In the year-to-date period, MRK achieves a 20.35% return, which is significantly lower than NVO's 23.68% return. Over the past 10 years, MRK has underperformed NVO with an annualized return of 12.92%, while NVO has yielded a comparatively higher 21.13% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
MRK vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Merck & Co., Inc. (MRK) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
MRK vs. NVO - Dividend Comparison
MRK's dividend yield for the trailing twelve months is around 2.30%, more than NVO's 0.77% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 2.30% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.42% | 3.11% | 3.45% |
NVO Novo Nordisk A/S | 0.77% | 0.71% | 0.84% | 0.94% | 1.33% | 1.51% | 1.97% | 1.52% | 2.87% | 0.92% | 1.43% | 1.23% |
Drawdowns
MRK vs. NVO - Drawdown Comparison
The maximum MRK drawdown since its inception was -68.63%, roughly equal to the maximum NVO drawdown of -71.28%. Use the drawdown chart below to compare losses from any high point for MRK and NVO. For additional features, visit the drawdowns tool.
Volatility
MRK vs. NVO - Volatility Comparison
The current volatility for Merck & Co., Inc. (MRK) is 4.22%, while Novo Nordisk A/S (NVO) has a volatility of 7.20%. This indicates that MRK experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
MRK vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Merck & Co., Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities